(Q39255639)

English

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

1 reference

based on heuristic

inferred from title

8

object named as

George W Sledge

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

author name string

Yesim Gökmen-Polar

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Yi Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Rachel A Toroni

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Kerry L Sanders

4

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Rutika Mehta

5

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Sunil Badve

6

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Christian Rommel

7

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

language of work or name

0 references

publication date

21 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

136

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

673-682

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Defining the role of mTOR in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Targeting the mTOR signaling network for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

An emerging role of mTOR in lipid biosynthesis.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

PI3K pathway alterations in cancer: variations on a theme

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

eIF-4E expression and its role in malignancies and metastases.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

The translational landscape of mTOR signalling steers cancer initiation and metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Involvement of chemokine receptors in breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

All roads lead to mTOR: integrating inflammation and tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Pushing the envelope in the mTOR pathway: the second generation of inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Prognostic value of vascular endothelial growth factor in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Identifiers

10.1007/S10549-012-2298-8

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39255639&oldid=2202727269"